IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Analyst Ratings
NASDAQ:IRWD - Nasdaq - US46333X1081 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 82% to IRWD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.75. This target is 454.35% above the current price.
IRWD was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about IRWD.
In the previous month the buy percentage consensus was at a similar level.
IRWD was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-01-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-01-22 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-09 | Leerink Partners | Initiate | Market Perform |
| 2024-08-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-08-09 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-05-10 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-03-01 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-02-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-01-17 | Craig-Hallum | Initiate | Buy |
| 2023-12-14 | Wells Fargo | Initiate | Overweight |
| 2023-09-28 | JMP Securities | Initiate | Market Outperform |
| 2023-05-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2022-08-16 | Wells Fargo | Maintains | Equal-Weight |
| 2022-04-22 | Piper Sandler | Initiate | Overweight |
| 2021-10-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-22 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-02-19 | Morgan Stanley | Maintains | Equal-Weight |